Johnson & Johnson
JNJ
ISIN US4781601046 / Valor 943981
Johnson & Johnson
UMushroom community rating:
About company
Johnson & Johnson is a diversified healthcare giant engaged in the research, development, and sale of pharmaceuticals, medical devices, and consumer health products. The company operates globally, with a significant focus on innovative medicine across multiple therapeutic areas including Oncology, Immunology, Neuroscience, Cardiovascular, Pulmonary Hypertension, and Retina. Johnson & Johnson is known for its commitment to addressing complex diseases and advancing the field of precision medicine, aiming to develop treatments that are personalized to individual genetic profiles. Through rigorous science and collaboration with healthcare professionals, the company strives to improve patient outcomes and lead in the discovery of groundbreaking medicines and technologies. Johnson & Johnson's approach combines cutting-edge research with a deep understanding of patient needs, aiming to not only treat diseases but also enhance the quality of life for people around the world.
Summarized from source with an LLMView SourceSector: HealthcareLatest Results (20.08.2024):
Revenue Growth
In the second quarter of 2024, Johnson & Johnson reported a total revenue of $24.189 billion, marking a 7.8% increase from the $22.439 billion reported in the same quarter of 2023. This growth was driven by strong performance across various segments and geographic areas.
Net Earnings
Johnson & Johnson's net earnings for the second quarter of 2024 were $4.686 billion, which represents a decrease of 12.8% compared to the $5.376 billion reported in the second quarter of 2023. The decline in net earnings was influenced by higher expenses and other financial factors.
Gross Profit
The gross profit for Johnson & Johnson in the second quarter of 2024 was $15.578 billion, up from $15.057 billion in the same period of 2023. This represents a gross profit margin of 69.4%, slightly lower than the 70.0% margin reported in the previous year.
Research and Development Expenses
Johnson & Johnson's research and development expenses for the second quarter of 2024 were $3.440 billion, a decrease of 7.1% from the $3.703 billion spent in the second quarter of 2023. The reduction in R&D expenses reflects the company's strategic prioritization of its investment in innovative medicines.
Dividends
Johnson & Johnson declared a quarterly dividend of $1.19 per share for the second quarter of 2024, consistent with the dividend paid in the same quarter of 2023. This reflects the company's commitment to returning value to its shareholders through consistent dividend payments.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
402178 M
Market cap (USD)
1,535,812
Daily traded volume (Shares)
167.25 / 165.79
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
Tej Ram Kumpakha
EQUITIES OF THE SAME SECTOR
